Last Updated: September 15, 2026
The Best Alternatives to ECT for Depression, Compared
Electroconvulsive therapy (ECT) can be very effective for depression, but it carries real trade-offs, including memory effects and the general anesthesia each session requires. If you are considering it, you may be wondering whether there is a way to find relief that asks less of you. Some alternatives come close to ECT in effectiveness and others do not. Drawing on head-to-head trials and large real-world studies, this article compares the leading options, ketamine and esketamine, TMS, VNS, and psilocybin therapy, on how well they work, how fast, how safe they are, and what each one asks of you.
Key takeaways
- ECT is believed to be the most effective treatment for severe depression, which is why guidelines still reserve it rather than replace it.¹
- Many people seek alternatives to avoid ECT's memory effects, anesthesia, relapse rate, and overall treatment burden, not because it is not effective.
- Less invasive options like ketamine therapy and TMS have been shown to be close to on par with ECT in overall effectiveness.²
- Other options, including VNS, DBS, and psilocybin therapy, are more limited or still investigational, currently reserved for chronic, last-line, or research settings.
Why People Look Past ECT (and When It's Still the Right Call)
People look past ECT mainly for three reasons: what it can do to memory, the general anesthesia and clinic schedule it requires, and how often depression returns afterward. None of that means ECT does not work. It is still widely considered the most effective treatment for severe depression, which is exactly why it stays on the table for the hardest cases.
ECT works, and it is still first-line for the most severe depression.
- In modern real-world data, about 73% of patients respond and 51% reach remission (Semple et al. 2024, Scottish national registry, n=2,074).³
- A 2024 network meta-analysis of treatment-resistant depression ranked ECT first of 25 treatments for response (Saelens et al. 2024).¹ A 2026 re-analysis has questioned that exact top ranking, but ECT is not in dispute as one of the most effective options available.
- It is strongest where other treatments struggle. In depression with psychotic features, remission reaches roughly 95% (Petrides et al. 2001), and guidelines often treat ECT as a first choice there, in catatonia, and in life-threatening episodes where a rapid response matters.⁴
Why people still want an alternative.
- Memory. Most cognitive effects are short-lived and recover within about two weeks of finishing treatment (Semkovska and McLoughlin 2010).⁵ A minority, about 12% in one large community study, experienced marked and lasting gaps in memory for personal events, with the risk rising the more bilateral treatments someone received (Sackeim et al. 2007).⁶
- Anesthesia and logistics. Each session uses general anesthesia, and a course is typically 6 to 12 sessions, two to three times a week, which means arranging transport and an escort home.
- Relapse. Even with continuation medication, relapse is common: about 38% within 6 months and 51% within 12 (Jelovac et al. 2013).⁷
- Stigma. Fair or not, ECT still carries cultural baggage that stops many people from considering it.
When ECT is still the right call. Major clinical guidelines (NICE, APA, VA/DoD 2022, CANMAT 2023) reserve ECT for severe, treatment-resistant, psychotic, or emergency depression, and they name the same alternatives covered here, rTMS and ketamine or esketamine, as options to try first in less severe treatment-resistant cases (VA/DoD 2022).⁸ For moderate depression, psychotherapy and medication remain the foundation. But for the treatment-resistant depression that usually raises the ECT question, talk therapy alone is rarely enough, which is why the neurostimulation and ketamine options below are the real comparison set.
The Alternatives to ECT at a Glance
Here is how the main alternatives stack up against ECT on the factors that usually decide the choice. Each is covered in depth in the sections that follow.
Transcranial Magnetic Stimulation (TMS) vs. ECT
TMS is the most widely used non-invasive alternative to ECT. Magnetic pulses stimulate the brain's mood-regulating region while you sit awake, with no anesthesia and no recovery, so you drive yourself home. The trade-off is pace: a standard course runs about 20 to 36 sessions over several weeks, though accelerated protocols like Stanford's SAINT reached about 90% remission in a five-day course and were FDA-cleared in 2022 (Cole et al. 2022).¹⁰ (See also our ketamine therapy vs. TMS guide.)
Is TMS as Effective as ECT?
Almost. On response the two are close; ECT keeps its edge on getting people all the way to remission.
- Response: In head-to-head trials, TMS and ECT show no significant difference (Terao et al. 2025).² Real-world registries put ECT higher, about 73% versus 57%, but ECT treats more severely ill patients, who have more room to improve, so that gap overstates the true difference (Sackeim et al. 2020; Semple et al. 2024).¹¹
- Remission: ECT gets more people to full remission, about 51% versus 28% in registries (Semple et al. 2024; Sackeim et al. 2020).³ Because remission is harder the more severe the starting point, that edge is likely real.
The bottom line: TMS comes close to ECT on response and asks far less of you: no anesthesia, no memory loss, no recovery. ECT still reaches full remission more often, so it remains the stronger choice for the most severe depression, but for many people TMS is the better first move.
Who it is a good fit for
- People with treatment-resistant depression who want to avoid anesthesia and memory effects.
- Those who live near a clinic and can commit to 20 to 36 sessions, often near-daily over several weeks.
- Less suited to severe, urgent, or psychotic depression, where ECT still leads.
Ketamine Therapy vs. ECT
Ketamine is the fastest-acting alternative to ECT, and the only one you can do at home. It is given as an IV or injection in a clinic, or as sublingual tablets or subcutaneous injections at home under clinician supervision, and it often lifts depression within hours to days rather than weeks. There is no anesthesia; the main in-session effect is a temporary, dreamlike sense of dissociation that fades within an hour or two.
Is Ketamine as Effective as ECT?
Close, though ECT keeps a slight edge. For non-psychotic depression the two are comparable; ECT pulls ahead in the most severe cases.
- Response: A network meta-analysis found no significant difference between ketamine and ECT (Terao et al. 2025), and direct trials land close.² In real-world use, response is about 54% for in-clinic IV ketamine (McInnes et al. 2022) and about 56% for Mindbloom's at-home tablets and injections (Mathai et al. 2024; Parks et al. 2026).¹²⁻¹⁴
- Remission: Real-world remission is about 28% for at-home ketamine and 29% for IV (Mathai et al. 2024; Parks et al. 2026; McInnes et al. 2022); direct trials put the two close here too.¹²⁻¹⁴
The bottom line: For non-psychotic depression, ketamine comes close to ECT with far less burden: no anesthesia, no memory effects, and an at-home option. The most acute relief may arrive a little sooner, though overall speed is comparable. ECT keeps its edge for the most severe and psychotic cases. Either way, relief is rarely permanent: like ECT, ketamine usually needs occasional maintenance sessions to hold gains. See our ketamine vs. ECT guide for the full head-to-head.
Who it is a good fit for
- People paying out of pocket, since at-home ketamine is among the most affordable supervised options, while ECT, IV ketamine, and Spravato cost far more without insurance.
- People who prefer treatment at home or do not live near a clinic, and who want to avoid anesthesia and memory effects.
- Less suited to severe psychotic depression or acute emergencies, where ECT still leads.
Esketamine (Spravato) vs. ECT
Esketamine is the FDA-approved nasal-spray form of ketamine, sold as Spravato. Approved for treatment-resistant depression in 2019 and cleared for use on its own in 2025, it is given in a certified clinic under monitoring, not at home. It is the only ketamine-based option with full FDA approval for depression; the racemic ketamine used for IV and at-home treatment is prescribed off-label, a common and legal practice.
Is Esketamine as Effective as ECT?
Approved, with more modest reported outcomes. Its reported response and remission tend to run below racemic ketamine and ECT, though it remains a real option where FDA approval matters.
- Response: Its pivotal trials showed a small benefit, and the trial in older adults missed its primary endpoint, at about 27% response (Ochs-Ross et al. 2020).¹⁵ A 24-trial meta-analysis found racemic ketamine produced roughly twice the response and remission of esketamine (Bahji et al. 2021).¹⁶
- Remission: Real-world remission is about 18% (Marci et al. 2025), below both racemic ketamine (about 28%) and ECT (about 51%).¹⁷
The bottom line: Esketamine's main advantage is its FDA approval, which can help with insurance coverage. It is given only in a clinic, and its reported outcomes tend to run a little below racemic ketamine or ECT.
Who it is a good fit for
- People who want an FDA-approved, potentially insurance-covered ketamine option.
- Those who live near a certified Spravato clinic and can attend monitored sessions.
- Less suited to anyone seeking the strongest ketamine response or an at-home option.
Vagus Nerve Stimulation (VNS) vs. ECT
VNS is a long-game option, not a fast fix. A small implanted device sends regular pulses to the vagus nerve, which connects to mood-regulating brain regions, running continuously in the background. FDA-approved in 2005, it is a last-line add-on for depression that has resisted at least four treatments, and Medicare has historically not covered it, tying access largely to research programs.
Is VNS as Effective as ECT?
Slow, but durable for some. VNS has not been compared to ECT directly, and its evidence is unusually mixed.
- Response: Both sham-controlled trials missed their primary endpoint (Rush et al. 2005; RECOVER trial, 2025).¹⁸⁻¹⁹ Its best figure is about 68% response over five years (Aaronson et al. 2017).²⁰
- Remission: About 43% over five years versus 26% on usual care (Aaronson et al. 2017), stronger in long-term follow-up than in the shorter controlled trials.²⁰
The bottom line: Benefit builds over months to years and can last once it takes hold, but it requires surgery and patience, which makes VNS a niche last-line option rather than a front-line alternative to ECT.
Who it is a good fit for
- People with long-standing depression that has resisted many treatments, including ECT.
- Those who live near a center that implants and manages the device and can accept surgery and a slow build for the chance of durable relief.
- Not a fit for anyone who needs relief soon or wants to avoid an implant.
Psilocybin Therapy vs. ECT
Psilocybin-assisted therapy is one of the most discussed directions in depression research. It pairs a supervised dosing session, using psilocybin, the active compound in certain mushrooms, with preparation and integration therapy, aiming for lasting change from a small number of guided sessions rather than a daily medication. For now it is available mainly through clinical trials, with limited exceptions in a few states, such as Oregon and Colorado, that have created supervised, regulated programs.
Is Psilocybin as Effective as ECT?
Early-stage but promising. No study has compared psilocybin to ECT head-to-head, and psilocybin's numbers come from controlled trials while ECT's come from real-world use, so the two cannot be lined up one to one.
- Response: About 37 to 42% in the largest controlled trials, and as high as roughly 70% in smaller ones (Goodwin et al. 2022; Raison et al. 2023).²¹⁻²² Controlled-trial rates run lower than the real-world figures reported for ECT, so the true gap is smaller than the raw numbers suggest.
- Remission: About 25 to 29% in the larger trials, and not always statistically significant (Goodwin et al. 2022; Raison et al. 2023).²¹⁻²² Remission is psilocybin's weaker measure.
The bottom line: Psilocybin's results place it among the effective options for depression, but on a far smaller and younger evidence base than ECT. It is a genuine contender for the future, not a proven stand-in today.
Who it is a good fit for
- People drawn to a small number of therapy-supported sessions rather than ongoing treatment.
- Those who live near, and can access, a clinical trial or a licensed state program.
- Not a fit for anyone who needs a proven, widely available treatment now, or who is in crisis.
Other Brain Stimulation Options: DBS and MST
Two more brain-stimulation approaches come up in conversations about severe depression, deep brain stimulation (DBS) and magnetic seizure therapy (MST). Both are investigational and rarely used outside research settings, so they are worth knowing about but are not options most people will be offered.
- Deep brain stimulation (DBS). Brain surgery to implant electrodes that deliver continuous stimulation to mood circuits, reserved for the most severe, otherwise untreatable depression. The evidence is unsettled: the two largest randomized trials did not outperform sham stimulation (Dougherty et al. 2015; Holtzheimer et al. 2017), though some patients improve over longer follow-up.²³⁻²⁴ It is not FDA-approved for depression.
- Magnetic seizure therapy (MST). An experimental relative of ECT that uses magnetic fields to induce a more focused seizure. Early research suggests antidepressant benefit approaching ECT with fewer memory and cognitive side effects (Cai et al. 2023), but it remains investigational and available in only a handful of centers.²⁵
Talking to Your Provider About the Right Option
There is no single best alternative to ECT. The right one depends on how severe your depression is, how fast you need relief, what side effects you can tolerate, where you can get treated, and what you can afford. A psychiatrist can match those to an option, and it helps to walk in with a few questions ready.
What shapes the decision
- Severity and urgency. For the most severe, psychotic, or emergency depression, ECT is still the first choice. For treatment-resistant depression short of that, guidelines support trying rTMS or ketamine or esketamine first (VA/DoD 2022; CANMAT 2023).⁸⁻⁹
- Speed. Ketamine and ECT work within days; TMS builds over weeks; VNS can take months.
- Side effects and burden. If avoiding anesthesia and memory effects matters most, TMS and ketamine stand out. If surgery or an implant is a dealbreaker, VNS and DBS are out.
- Setting. Most options mean regular in-clinic visits; at-home ketamine is the exception.
- Cost. Without insurance, ECT, IV ketamine, and esketamine are expensive. Mindbloom's at-home program runs roughly $165 to $215 per session, among the most affordable supervised options.
Questions worth asking
- Given my history, is ECT actually recommended, or is it reasonable to try an alternative first?
- Which option fits my depression's severity and how quickly I need to feel better?
- What will this cost me, with and without insurance?
Frequently asked questions
How severe does depression need to be for ECT?
ECT is generally reserved for severe, treatment-resistant, psychotic, or life-threatening depression, or when a fast response is critical and other treatments have not worked. For moderate depression, medication, therapy, and options like TMS or ketamine are usually tried first (VA/DoD 2022).⁸
Can therapy alone replace ECT?
For moderate depression, psychotherapy such as CBT is a foundation of treatment and can be enough on its own. But for the severe, treatment-resistant depression that usually raises the question of ECT, talk therapy alone is rarely sufficient, and it is typically combined with medication or one of the alternatives covered here.
Which alternative to ECT works fastest?
Ketamine is the fastest, with some people feeling relief within hours to days. ECT also works quickly, over days to about two weeks. TMS builds gradually over several weeks, and VNS can take months.
Do alternatives to ECT cause memory loss?
No. The top alternatives to ECT including TMS, ketamine, esketamine, and VNS are not linked to the lasting memory loss some people experience after ECT, which is one of the main reasons people look for another option.
Are any alternatives as effective as ECT?
Some come close. In head-to-head trials, the leading alternatives, ketamine and TMS, show no statistically significant difference from ECT in response (Terao et al. 2025). But ECT still holds a slight overall edge, clearest on full remission and in severe or psychotic depression, where it remains the most effective option. For many people, that small gap is worth the lower burden of ketamine or TMS.
Does insurance or Medicare cover alternatives to ECT?
Coverage varies. TMS and esketamine are widely covered for treatment-resistant depression, and ECT is generally covered. Racemic ketamine is usually out of pocket because it is used off-label, though at-home programs are among the most affordable options. VNS coverage has historically been limited. Check with your insurer about your specific plan.
Do natural or traditional remedies work as alternatives to ECT?
For severe, treatment-resistant depression, there is no good evidence that supplements, herbal products, or traditional remedies can substitute for ECT or the medical treatments covered here. They may support milder symptoms, but they are not alternatives for the depression that leads people to consider ECT.
Mindbloom Treatment
See what might be possible with clinician-guided, at-home ketamine therapy. New client programs start at $165 per session.
Authors
